WHO wants to be ready: Global health body wants to draft essential meds, vaccines for poorer nations to Covid repeat
The draft also looks set to continue a long-running argument by calling for intellectual property rights to be waived during pandemics, which advocates say would allow for wider access to life-saving drugs and vaccines more quickly
London: Governments may have to reserve drugs and vaccines for the World Health Organization to distribute in poorer countries to avoid a repeat of the “catastrophic failure” during the COVID-19 pandemic, according to an early draft of a global pandemic agreement.
One of the most concrete proposals in the draft accord reviewed by Reuters on Wednesday includes a measure to reserve 20 per cent of any tests, vaccines or treatments developed for use in poorer countries.
The draft also looks set to continue a long-running argument by calling for intellectual property rights to be waived during pandemics, which advocates say would allow for wider access to life-saving drugs and vaccines more quickly.
The pharmaceutical industry is against the move.
The draft also retains earlier provisions that could see pharmaceutical companies made to release details of any public contracts for vaccines and treatments during such global health emergencies.
The agreement, which is commonly known as the pandemic treaty, has been drawn up by WHO member states and will now go through a lengthy negotiating process before being finalised.
Talks on the draft treaty will begin on February 27 and are set to continue to 2024. Member states have agreed that the treaty will be legally binding for those who sign up, but it is not yet clear how that will be enforced.
The draft was released to member states and non-governmental organisations (NGOs) on Wednesday. It contains a number of measures to ensure the world’s response to the next pandemic is not only more robust, but more equitable.
“It is a once-in-a-generation chance to make a paradigm shift in the protection and improvement of the health of the world’s people,” WHO spokesperson Fadela Chaib said of the accord.
The draft begins by saying it is being drawn up “in recognition of the catastrophic failure of the international community in showing solidarity and equity in response to the coronavirus disease (COVID-19) pandemic”.
However, there will be “heat and opposition” in the negotiations ahead, particularly around the intellectual property provisions, said James Love, director of the NGO Knowledge Ecology International.
“The ‘accord’ should build on the private sector’s strengths for innovative R&D, quick manufacturing scaling up and distribution, which is built on a robust intellectual property system,” said Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations.
The draft also calls for a new WHO Global Pandemic Supply Chain and Logistics Network to ensure better and fairer distribution of counter-measures, as well as a global compensation scheme for vaccine injuries.
It also proposes the WHO Pathogen Access and Benefit-Sharing System, which urges countries to share pathogens and genomic sequences “within hours”.
Diagnostics, treatments and vaccines developed from the data should be shared fairly, including a provision that the WHO gets 20% of any production – 10% as donation and the rest at affordable prices – for use in developing countries, the document suggests.
The plan aims to avoid countries sharing data on outbreaks not getting access to counter-measures developed using the data.
“The provisions on transparency and equity are impressive,” Love said, “but I think negotiators need to do more work on how to create incentives for governments and others to both invest and share technologies”.
Read all the Latest News, Trending News, Cricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.
COVID-19 pill Paxlovid moves closer to full FDA approval
The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021. The agency has the final say on giving Pfizer's drug full approval and is expected to decide by May.
COVID or flu? This device will tell you in just 10 seconds
It can detect and differentiate between the presence of various viral proteins because of its extreme thinness, which makes it so sensitive to any electrical changes in its environment
Joe Biden signs law declassifying US intel on COVID-19 origin
Biden said that in 2021, after taking office, he had 'directed the Intelligence Community to use every tool at its disposal to investigate'